Prospecto: information for the patient
Rolpryna SR2mg prolonged-release tablets EFG
ropinirol
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What is Rolpryna SR and what is it used for
2.What you need to know before starting to take Rolpryna SR
3.How to take Rolpryna SR
4.Possible adverse effects
5Storage of Rolpryna SR
6.Contents of the pack and additional information
The active ingredient of Rolpryna SR is ropinirol, which belongs to a group of medications called dopamine agonists. Dopamine agonists act in the same way as a natural substance found in the brain, called dopamine.
Rolpryna SR prolonged-release tablets are used for the treatment of Parkinson's disease.
People with Parkinson's disease have low levels of dopamine in certain parts of the brain. Ropinirol has a similar effect to natural dopamine and, in this way, reduces the symptoms of Parkinson's disease.
DO NOT TAKERolpryna SRif:
Inform your doctor if you think you may be in any of these situations.
Warnings and Precautions
Consult your doctor or pharmacist before starting to takeRolpryna SR:
Inform your doctor if you think you may be in any of these situations. Your doctor will decide if your treatment withRolpryna SRis suitable for you, or if you need any additional monitoring while taking it.
Inform your doctor if you or your family/caregiver notice that you are developing any abnormal behavior or if you cannot resist impulses, or if you have thoughts of doing things that could be harmful to yourself or others. This is known as impulse control disorder and may include behaviors such asexcessive gambling, excessive eating or compulsive eating, compulsive shopping, or an abnormal increase in sexual desires or behaviors.Your doctor may need to adjust or stop your treatment.
Inform your doctor if you notice symptoms such as depression, apathy, anxiety, fatigue, sweating, or pain when stopping or reducing treatment with ropinirol (known as dopamine agonist withdrawal syndrome or SAAD).If the problems persist after a few weeks, your doctor may need to adjust your treatment.
Inform your doctor if you or your family/caregiver notice that you are developing episodes of hyperactivity, euphoria, or irritability (symptoms of mania). These may occur with or without symptoms of impulse control disorder (see above).Your doctor may need to adjust or stop your treatment..
While Taking Rolpryna SR
Inform your doctor if you or your family/caregiver notice that you are developing anyabnormal behavior(such as anexcessive need to gambleor anincrease in sexual desires or behaviors) while taking Rolpryna SR. Your doctor may need to adjust or stop your treatment.
Smoking and Rolpryna SR
Inform your doctorif you have started or stopped smoking while takingRolpryna SR.Your doctor may need to adjust your dose.
Other Medications and Rolpryna SR
Inform your doctor or pharmacist if you aretaking, have taken recently, or may need to take any other medication,including medications based on plants or those obtained without a prescription.
Remember to inform your doctor or pharmacist if you start taking a new medication while takingRolpryna SR.
Some medications may affect the effect ofRolpryna SRor make it more likely that you will experience side effects.Rolpryna SRmay also alter the way other medications work.
These medications include:
Inform your doctor if you are taking, or have taken recently, any of these medications.
You will need to undergo additional blood testsif you are taking these medications with Rolpryna SR:
Taking Rolpryna SR with Food and Drinks
You can takeRolpryna SRwith or without food.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
This medication is not recommended during pregnancy, unless your doctor tells you that the benefits for you outweigh any possible risks for the fetus. Rolpryna SR should not be used during breastfeeding, as milk production may be affected.
Inform your doctor immediately if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will advise you what to do if you are breastfeeding or plan to breastfeed. Your doctor may recommend that you stop treatment with Rolpryna SR.
Driving and Operating Machinery
Rolpryna SRmay make you feel drowsy. In rare casesRolpryna SRmay make you feel extremely drowsy, and in some cases it may cause you tofall asleep suddenly without warning. It may also cause hallucinations.
If you experience this:do not drive, do not operate machinery, anddo notput yourself in situations where feeling drowsy or falling asleep could put you (or others) at risk of serious harm or death. Do not engage in these activities until you are no longer affected.
Rolpryna SR contains lactose
This medicationcontains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist.This medication should be taken exactly as directed.In case of doubt, consult your doctor or pharmacist again.
Use in children and adolescents
Do not give Rolpryna SR to children.Rolpryna SR is not normally prescribed to individuals under 18 years of age.
You may have been prescribed Rolpryna SR only for the treatment of your Parkinson's disease symptoms, or you may also have been prescribed another medication called L-dopa (also known as levodopa). If you are taking L-dopa, you may experience some uncontrollable sudden movements (dyskinesias) when you start taking rolprinirol. Consult your doctor if this occurs, as you may need to adjust the doses of L-dopa and other medications you are taking.
The Rolpryna SR tablets have been designed to release the drug over a period of 24 hours. If you have any condition that makes the medication pass through your body too quickly, such as diarrhea, it is possible that the tablets will not dissolve completely and will not act correctly. You may see the tablets in your stool. If this occurs, inform your doctor as soon as possible.
What dose of Rolpryna SR should you take?
You may need some time to determine what dose of Rolpryna SR is best for you.
Initial recommended doseof Rolpryna SR prolonged-release tablets is 2 mg once a day during the first week.From there, your doctor may increase the dose to 4 mg of Rolpryna SR prolonged-release tablets once a day, during the second week of treatment. In older individuals, your doctor may increase the dose more slowly. After that, your doctor may adjust the dose to reach the most suitable dose for you. Some people may take up to 24 mg of Rolpryna SR prolonged-release tablets each day.
If you experience side effects at the start of your treatment that you cannot tolerate, consult your doctor. Your doctor may advise you to switch to a lower dose of ropinirol film-coated tablets (immediate-release) that you will take three times a day.
Do not take more Rolpryna SR tablets than your doctor has prescribed.
You may need several weeks for ropinirol to take effect.
How to take your Rolpryna SR dose
Take Rolpryna SR once a day, at the same time of day.
Swallow the Rolpryna SR tablets whole, with a glass of water.
Do not break, chew, or crush the prolonged-release tablets. If you do, there may be a risk of receiving an excessive dose, as the medication will be released into your body too quickly.
If you switch from ropinirol film-coated tablets (immediate-release)
Your doctor will adjust your dose of Rolpryna SR prolonged-release tablets based on the dose of ropinirol film-coated tablets (immediate-release) you are taking.
Take your ropinirol film-coated tablets (immediate-release) as usual the day before the switch. Then, take your Rolpryna SR prolonged-release tablets in the morning, and do not take any more ropinirol film-coated tablets (immediate-release).
If you take more Rolpryna SR than you should
If you have taken more Rolpryna SR than you should, consult your doctor or pharmacist, go to the nearest hospital immediately, or call the Toxicological Information Service. Phone: 91 562 04 20, indicating the medication and the amount ingested. If possible, show them the packaging.
Someone who has suffered a Rolpryna SR overdose may have some of the following symptoms: nausea, vomiting, dizziness, somnolence, fatigue (mental or physical tiredness), feeling of fainting, hallucinations.
If you forget to take Rolpryna SR
Do not take extra tablets or a double dose to compensate for the missed dose.
If you have forgotten to take Rolpryna SR for one or several days, consult your doctor to have them recommend how to start taking it again.
If you interrupt the treatment with Rolpryna SR
Do not interrupt the treatment with Rolpryna SR without consulting your doctor.
Take Rolpryna SR for the time your doctor indicates. Do not suspend the treatment unless your doctor tells you to.
If you suddenly stop taking Rolpryna SR, your Parkinson's disease symptoms may worsen rapidly.
Do not stop taking Rolpryna SR suddenly without consulting your doctor.
A sudden interruption could cause the development of a condition called neuroleptic malignant syndrome, which may pose a significant risk to your health. The symptoms are akinesia (loss of muscle movement), muscle rigidity, fever, unstable blood pressure, tachycardia (increased heart rate), confusion, depressed level of consciousness (e.g., coma).
If you need to stop your Rolpryna SR treatment, your doctor will gradually reduce the dose.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines,this medicinecan cause side effects, although not everyone will experience them.
The side effects of Rolpryna SR are more likely to occur at the beginning of treatment, or when the dose is increased. These are generally mild and may be less bothersome over time. Inform your doctor if you are concerned about side effects.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Some patients may experience the following side effects(frequency not known:cannot be estimated from available data):
Inform your doctor if you experience any of these behaviors, he will advise you on how to manage or reduce symptoms.
If you are taking Rolpryna SR with L-dopa
People taking Rolpryna SR with L-dopa may develop other side effects over time:
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep out of reach and sight of children.
Do not use Rolpryna SR after the expiration date that appears on the packaging and blister after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Store in the original packaging to protect it from humidity.
Medicines should not be thrown down the drains or in the trash. Dispose of the containers and the
medicines that you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and the medicines that you no longer need. In this way, you will help protect the environment.
Composition ofRolpryna SR 2 mgprolonged-release tablets
Tablet core:hypromellose 2208, lactose monohydrate, anhydrous colloidal silica, carbomer 4.000-11.000 mPa.s, hydrogenated ricin oil, magnesium stearate.
Covering::hypromellose 2910, dioxide of titanium (E171),macrogol 400, red iron oxide (E172), yellow iron oxide (E172).See section 2“Rolpryna SR contains lactose”.
Appearance of the product and contents of the pack
Rolpryna SR 2 mgareprolonged-release tabletsofpink color, biconvex and oval.
The tablets are available in packs of 21, 28, 42 and 84 prolonged-release tablets in blister (OPA/Al/PVC//Al).
Only some pack sizes may be marketed.
Marketing authorization holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Responsible for manufacturing
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501, Novo mesto, Slovenia
TAD PHARMA GmbH Heinz Lohmann strasse, 5 D-27472 Cuxhaven, Germany
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Name of the member state | Name of the medicinal product |
Bulgaria, Estonia, Latvia, Lithuania, Poland, Slovakia, Slovenia, Spain | Rolpryna SR |
Czech Republic | Rolpryna |
Norway, Portugal | Ropinirol Krka |
Romania | Rolpryna EP |
Last revision date of this leaflet:July 2023
The detailed information about this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.